Sökning: onr:"swepub:oai:DiVA.org:oru-6999" > Treatment of primar...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 05506naa a2200649 4500 | |
001 | oai:DiVA.org:oru-6999 | |
003 | SwePub | |
008 | 090528s2008 | |||||||||||000 ||eng| | |
009 | oai:DiVA.org:umu-46046 | |
009 | oai:lup.lub.lu.se:258f82f9-f9df-43c4-9dfb-9a04419d274f | |
009 | oai:DiVA.org:liu-45900 | |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-69992 URI |
024 | 7 | a https://doi.org/10.1111/j.1525-1438.2007.01094.x2 DOI |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-460462 URI |
024 | 7 | a https://lup.lub.lu.se/record/12549372 URI |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-459002 URI |
040 | a (SwePub)orud (SwePub)umud (SwePub)lud (SwePub)liu | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a art2 swepub-publicationtype |
100 | 1 | a Sorbe, Bengtu Örebro universitet,Hälsoakademin,Department of Gynecological Oncology, University Hospital, Örebro, Sweden, Department of Gynecological Oncology, University Hospital, SE-701 85 Örebro, Sweden4 aut0 (Swepub:oru)bse |
245 | 1 0 | a Treatment of primary advanced and recurrent endometrial carcinoma with a combination of carboplatin and paclitaxel-long-term follow-up |
264 | 1 | b Blackwell Publishing Ltd,c 2008 |
338 | a print2 rdacarrier | |
520 | a There is no generally accepted standard chemotherapy in treatment of advanced and recurrent endometrial carcinoma. Cisplatin and doxorubicin with or without cyclophosphamide are widely used. Response rates have improved with combination chemotherapy compared with single-agent therapy. A platinum analog seems to be an important part of the chemotherapy regimen. Since few patients are cured from their disease and since the duration of response is short, further improvement of this therapy is warranted. During the past years, the taxanes (paclitaxel) are being added to prior evaluated regimens and not only improved response rates are reported but also increased toxicity is observed. In a prospective, phase II, multicenter study, carboplatin (area under the curve = 5) and paclitaxel (175 mg/m(2)) were evaluated in treatment of primary advanced and recurrent endometrial carcinoma. In total, 66 patients were recruited during the years 2000-2004. Eighteen primary advanced tumors and 48 recurrences were treated. All histologic types and tumor grades were allowed. The median follow-up was 57 months (range 37-69 months). The overall response rate was 67% (95% CI 55-78). The complete response rate was 29% and the partial response rate 38%. Primary advanced and recurrent tumors as well as endometrioid and nonendometrioid tumors showed similar response rates. The median response duration was 14 months. The 1- and 3-year survival rates were 82% and 33%, respectively. The main toxicities were hematologic and neurologic (sensory neuropathy). The response rates were encouraging, superior to prior platinum-containing regimens, but response duration and the long-term survival rate were still short. The neurologic toxicity was frequent and was a substantial problem in this series of patients. Further research is highly needed to improve the treatment of advanced and recurrent endometrial cancer. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Reproduktionsmedicin och gynekologi0 (SwePub)302202 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Obstetrics, Gynaecology and Reproductive Medicine0 (SwePub)302202 hsv//eng |
653 | a Taxol | |
653 | a carboplatin | |
653 | a endometrial cancer | |
653 | a MEDICINE | |
653 | a MEDICIN | |
653 | a Oncology | |
653 | a Onkologi | |
653 | a Obstetrics and gynaecology | |
653 | a Obstetrik och gynekologi | |
653 | a Oncology | |
653 | a onkologi | |
653 | a chemotherapy | |
653 | a carboplatin | |
653 | a paclitaxel | |
653 | a endometrial cancer | |
700 | 1 | a Andersson, Hu Department of Gynecological Oncology, University Hospital, Gothenburg, Sweden4 aut |
700 | 1 | a Boman, Karinu Umeå universitet,Onkologi,Department of Gynecological Oncology, University Hospital, Umeå, Sweden4 aut0 (Swepub:umu)kabo0010 |
700 | 1 | a Rosenberg, Peru Östergötlands Läns Landsting,Linköpings universitet,Hälsouniversitetet,Onkologi,Onkologiska kliniken US4 aut0 (Swepub:liu)perro95 |
700 | 1 | a Kalling, Mårtenu Lund University,Lunds universitet,Sektion V,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Section V,Department of Clinical Sciences, Lund,Faculty of Medicine,Department of Gynecologic Oncology, University Hospital, Lund, Sweden4 aut0 (Swepub:lu)extLU-138 |
710 | 2 | a Örebro universitetb Hälsoakademin4 org |
773 | 0 | t International Journal of Gynecological Cancerd : Blackwell Publishing Ltdg 18:4, s. 803-808q 18:4<803-808x 1048-891Xx 1525-1438 |
856 | 4 | u http://dx.doi.org/10.1111/j.1525-1438.2007.01094.xy FULLTEXT |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-6999 |
856 | 4 8 | u https://doi.org/10.1111/j.1525-1438.2007.01094.x |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-46046 |
856 | 4 8 | u https://lup.lub.lu.se/record/1254937 |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-45900 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
Kopiera och spara länken för att återkomma till aktuell vy